4.6 Review

Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 45, Issue -, Pages 53-64

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2019.01.002

Keywords

Progranulin; Membrane receptors; Inflammation; Autoimmune diseases; Neurodegenerative diseases; Cancer; Lysosomal storage diseases

Funding

  1. NIH [R01NS103931, R01AR062207, R01AR061484]
  2. DOD [W81XWH-16-1-0482]
  3. National Natural Science Foundation of China [81772300]

Ask authors/readers for more resources

Progranulin (PGRN), a widely expressed glycoprotein with pleiotropic function, has been linked to a host of physiological processes and diverse pathological states. A series of contemporary preclinical disease models and clinical trials have evaluated various therapeutic strategies targeting PGRN, highlighting PGRN as a promising therapeutic target. Herein we summarize available knowledge of PGRN targeting in various kinds of diseases, including common neurological diseases, inflammatory autoimmune diseases, cancer, tissue repair, and rare lysosomal storage diseases, with a focus on the functional domain-oriented drug development strategies. In particular, we emphasize the role of extracellular PGRN as a non-conventional, extracellular matrix bound, growth factor-like conductor orchestrating multiple membrane receptors and intracellular PGRN as a chaperone/co-chaperone that mediates the folding and traffic of its various binding partners.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available